Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.66 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090161 | 1.00 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNA1CHRNB1CHRNB4 | |
| SCHEMBL13188207 | 0.91 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA1CHRNB1CHRNB4 | |
| SCHEMBL31742565 | 0.84 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA1CHRNB1CHRNB4 | |
| SCHEMBL171896 | 0.82 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL392062 | 0.82 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL23745944 | 0.82 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA1CHRNB1CHRNB4 | |
| SCHEMBL30338591 | 0.82 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL28046302 | 0.81 | CYP3A4 (0.74) | CYP3A4CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL422229 | 0.81 | CYP2C9 (0.70) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| Ammonia Solution, Strong SCHEMBL7207615 | 0.81 | CHRNB2 (0.66) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-02 | — | — | US | disclosed |
| US-20220378762-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378762-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | EGFR, ERBB2, ERBB4 | CHRNB2 4740/4885CHRNA4 4815/4885CHRNA1 4729/4885 |
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | EGFR, ERBB2, ERBB4 | CHRNB2 4740/4885CHRNA4 4815/4885CHRNA1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.